April 1, 2015 – NEW YORK — Brian Mehling, M.D., a board-certified orthopedic trauma surgeon and CMO of Blue Horizon International (BHI), will deliver his presentation “Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation”
This groundbreaking event will bring together engineering and orthopaedic clinicians and researchers to exchange ideas and foster innovation in orthopaedic devices and spur economic development in Ohio. Medical students, residents and fellows, biomedical engineering students of all levels, students from biomedical sciences and advisors are invited to participate in this open forum to develop strong academic and industry partnerships.
Dr Mehling said: “Stem cell research plays an important role in orthopaedic regenerative medicine today. Arthritis literally means “inflammation of a joint.” Mesenchymal Stem Cells (MSCs) represent a valuable tool for therapy of symptoms related to chronic inflammatory diseases.”
The purpose of this study is primarily to monitor the immune response in order to validate the safety of intravenous infusion of human umbilical cord blood derived MSCs (UC-MSCs), and secondly, to evaluate effects on biomarkers associated with chronic inflammation.
“Stem cells are the future of medicine and we believe their role in treatments will become the preferred substitutes for many surgical, pharmacological, and rehabilitative medical services,” Dr. Mehling said. “This conference provides an opportunity for BHI to educate and raise awareness on an international stage. It is an informative and important discussion on the revolutionary changes in the treatment of many chronic conditions, disorders, and acute diseases.”